Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Phase 3Symphony™ IL-6Positive

AI Analysis

Summary

Bluejay Diagnostics announced successful completion of enrollment in the SYMON-II pivotal study with 750 patients evaluating Symphony™ IL-6 for sepsis mortality risk assessment, ahead of schedule.

Clinical Trial Data

Phase

Phase 3

Patients

750

Outcome Details

Enrollment completed ahead of plan with 750 patients

Importance:6/10

Sentiment:

0.70

clinical trialenrollment completesepsisdiagnosticsSYMON-II

Related Companies

$BJDX

Read the original article

Published by GlobeNewswire Clinical Studies on July 21, 2026 10:30 AM

Read Original